For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Adding stereotactic body radiotherapy to enzalutamide and ADT for oligometastatic castration-resistant prostate cancer prolongs radiographic progression-free survival. Adding metastasis-directed ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

Researchers sought to assess the strategies used for training hematology/oncology nurses in assessing cancer patients’ lower extremities for skin issues and edema.

The following is a summary of “Multicentre cross-sectional study to assess nursing workload in Belgian emergency departments,” published in the February 2025 issue of Emergency Medicine Journal by ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

Patients were also on androgen receptor pathway inhibitors during the trial, most commonly enzalutamide. Men in the trial started out on three patches, which were changed twice a week, then ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.

USA Health University has introduced a new mental health and well-being program designed specifically to address burnout and ...

The agency turned down use of Roche’s Perjeta (pertuzumab) for the adjuvant treatment of early stage breast cancer as well as Pfizer’s Xtandi (enzalutamide) for early-stage prostate cancer ...